Nihon Medi Physics Co.

Tokyo, Japan

Nihon Medi Physics Co.

Tokyo, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Yokohama City University and Nihon Medi Physics Co. | Date: 2017-05-17

A novel technique of quantifying nuclear medicine data is provided. The novel technique is characterized in that information acquired from nuclear medicine image data is normalized with bone mineral content (BMC) or bone mineral density (BMD). Some embodiments use, instead of the conventional SUV, the SUVbone that has been invented by the inventors of the present application such as the following: SUVbone = {Amount of attenuation-corrected radioactivity in region of interest (kBq) Volume of region of interest (ml)} / {Administered radioactivity dose (kBq) Bone mineral content (g)} or SUVbone = {Amount of attenuation-corrected radioactivity in region of interest (kBq) Volume of region of interest (ml)} / {Administered radioactivity dose (kBq) Bone mineral density (g/m^(2))}. BMC or BMD may be estimated from sex, age, height, or weight of a subject.


Patent
Nihon Medi Physics Co. | Date: 2017-05-17

To provide a technique for evaluating a nuclear medicine brain image, the technique being hardly affected by the difference in the setting of reference regions. An embodiment of the present invention generally includes: setting a reference region on a region corresponding to the scalp in the nuclear medicine brain image; calculating information on a pixel value in the set reference region; and normalizing, using the information, a pixel value of each pixel included in the nuclear medicine brain image or a value obtained from the pixel value, and outputting the normalized value.


Disclosed is a target device (10) having a plurality of target material plates (20a, 20b) for producing a radionuclide, lined up in an overlapped manner, configured to produce the radionuclide when a particle beam is irradiated on the target material plates (20a, 20b), the target device (10) having a front plate group (GRF) composed of target material plates (20a) positioned to the front side the particle beam comes in, and a rear plate group (GRR) composed of the target material plates (20b) positioned to the rear side, and the average thickness of the target material plates (20a) composing the front plate group (GRF) being smaller than the average thickness of the target material plates (20b) composing the rear plate group (GRR).


Patent
Nihon Medi Physics Co. | Date: 2017-08-02

The present invention provides a renal imaging agent comprising a nitroimidazole-type compound or a salt thereof. The renal imaging agent according to the present invention can be used in positron emission tomography.


There is provided a labeling precursor compound represented by the following general formula (2):_(1) represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R_(2) and R_(3) each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R_(6) represents an alkyl group or -CONR_(11)R_(12) wherein R_(11) and R_(12) each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R_(4), R_(5), R_(7) and R_(8) each independently represent a hydrogen atom, an alkyl group or an alkoxy group.


There is provided a labeling precursor compound represented by the following general formula (2): wherein R_(1 )represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R_(2 )and R_(3 )each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R_(6 )represents an alkyl group or CONR_(11)R_(12 )wherein R_(11 )and R_(12 )each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R_(4), R_(5), R_(7 )and R_(8 )each independently represent a hydrogen atom, an alkyl group or an alkoxy group.


Patent
Nihon Medi Physics Co. | Date: 2017-06-07

One embodiment of the present invention addresses the problem of reducing the influence of physiological accumulation in monitoring nuclear medical image data. To solve this problem, the embodiment comprises: extracting a bone area from CT image data having been positioned with nuclear medical image data; in the nuclear medical image data, displaying the data of an area overlapping the bone area extracted above; and, in the nuclear medical image data, not displaying the data of an area not overlapping the bone area extracted above.


Patent
Nihon Medi Physics Co., Kyoto University and National Hospital Organization | Date: 2015-06-25

Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R_(1), R_(2), R_(3), R_(4), R_(5), X_(1), X_(2), and X_(3 )are defined.


Patent
Nihon Medi Physics Co., Kyoto University and National Hospital Organization | Date: 2017-05-03

Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. (In the formula, R_(1) represents a hydrogen atom or CO_(2)R_(a); R_(2) represents a hydrogen atom, a halogen atom, or CO_(2)R_(a); R_(3) represents a hydrogen atom or a C1-10 hydroxyalkyl group; R_(4) represents a hydrogen atom, a hydroxy group, or a C1-10 alkoxy group; R_(5) represents a C1-5 chain alkyl group in which the hydrogen atoms are optionally substituted with halogen atoms, a C3-5 cyclic alkyl group in which the hydrogen atoms are optionally substituted with halogen atoms, a C1-5 hydroxyalkyl group, or an o-, p-, or m-halobenzyl group; A represents CH or a nitrogen atom; X_(1) and X_(3) independently represent hydrogen atoms or halogen atoms; X_(2) represents a hydrogen atom, a halogen atom, or a nitrile group; at least one of X_(1), X_(2), and X_(3) represents a halogen atom; and R_(a) independently represents a C1-10 alkyl group.)


Provided is a method for producing an animal model of osteoblastic bone metastasis. A non-human animal in which an osteoblastic lesion is formed in a wide range has been successfully produced with a probability of 100% by: administering a calcineurin inhibitor to a non-human animal, and injecting a tumor cell into an artery or a vein of the non-human animal, wherein the non-human animal and the tumor cell are in an allogeneic or xenogeneic relation.

Loading Nihon Medi Physics Co. collaborators
Loading Nihon Medi Physics Co. collaborators